Invest in women’s health
A massive underserved market with a clear pathway to AI-powered endometriosis detection
£6.5M
Series A Target
190M
Women affected globally
8+ Yrs
Diagnostic Delay
£10+BN
Addressable Market
INVESTMENT THESIS
WHY ENDOSCAN.ai
MASSIVE UNDERSERVED MARKET
ENDOMETRIOSIS AFFECTS 10% OF WOMEN GLOBALLY, WITH CHRONIC UNDERDIAGNOSIS CREATING ENORMOUS UNMET DEMAND FOR ACCESSIBLE, NON-INVASIVE DIAGNOSTICS.
PROPRIETARY DATA MOAT
OUR LIVE CLINIC GENERATES EXPERT-ANNOTATED TRAINING DATA WITH EVERY SCAN — A COMPOUNDING ADVANTAGE COMPETITORS CANNOT EASILY REPLICATE.
CLEAR REGULATORY PATHWAY
CQC-REGISTERED CLINICAL SERVICE WITH CLINICIAN-IN-THE-LOOP AI — AVOIDING DELAYS OF STANDALONE MEDICAL DEVICE CERTIFICATION.
EXPERIENCED TEAM
SPECIALIST CLINICAL LEADERSHIP, DEEP AI AND CLOUD INFRASTRUCTURE EXPERTISE, AND PROVEN OPERATIONAL CAPABILITY DRIVING THE TECHNOLOGY FORWARD.
Request our investor pack
Chat with us